Research·October 20, 2026 at 11:55 AM EDT·2 sources
New ICER report suggests drug launch prices are outpacing their worth
Outlets covering it2 in 2 hours
Oct 20, 3 PMOct 20, 5 PM
What happened
- ICER found that most new medicines launched between 2022 and 2025 were priced above its cost-effectiveness guidelines.
- Median list prices at launch rose 24% from 2022 to 2025.
- Net launch prices rose even more sharply during the period, according to ICER.
Increase in median list price at launch, 2022-2025
24%
Why it matters
The findings could influence drug-pricing scrutiny, payer negotiations and policy discussions about whether launch prices reflect clinical value.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- First reported by BioPharma DiveOct 20Most new drugs are still too costly at launch, ICER says
- Endpoints News reportsOct 20New ICER report suggests drug launch prices are outpacing their worth
Sources (2)
- BioPharma DiveOct 20Most new drugs are still too costly at launch, ICER says
- Endpoints NewsOct 20New ICER report suggests drug launch prices are outpacing their worth
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.